Holen Sie sich die Stockscreener-App
0.267
2.65%
0.0069
Handel nachbörslich:
.27
0.003
+1.12%
Schlusskurs vom Vortag:
$0.2601
Offen:
$0.2653
24-Stunden-Volumen:
542.07K
Relative Volume:
0.22
Marktkapitalisierung:
$8.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.71M
KGV:
-0.0228
EPS:
-11.71
Netto-Cashflow:
$-18.24M
1W Leistung:
-9.98%
1M Leistung:
+1.17%
6M Leistung:
-64.49%
1J Leistung:
-86.45%
1-Tages-Spanne:
$0.263
$0.2755
1-Wochen-Bereich:
$0.248
$0.3099
52-Wochen-Spanne:
$0.2023
$3.97
Genprex Inc Stock (GNPX) Company Profile
Firmenname
Genprex Inc
Sektor
Branche
Telefon
512-537-7997
Adresse
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Vergleichen Sie GNPX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.267 | 8.60M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-26 | Eingeleitet | National Securities | Buy |
| 2019-04-29 | Eingeleitet | Noble Capital Markets | Outperform |
Genprex Inc Aktie (GNPX) Neueste Nachrichten
Genprex Inc. Stock Analysis and ForecastRapid growth trajectories - jammulinksnews.com
What analysts say about Genprex Inc. stockSuperior stock growth - jammulinksnews.com
Is Genprex Inc. a good long term investmentSuperior capital gains - Autocar Professional
What drives Genprex Inc. stock priceRemarkable growth - jammulinksnews.com
How Genprex Inc. stock performs during market volatilityMulti Bagger Alerts - Newser
Genprex (NASDAQ:GNPX) Stock Price Down 3.2% – Should You Sell? - Defense World
What makes Genprex Inc. stock price move sharplyFree Investment Group - beatles.ru
how genprex inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
Why Genprex Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
Genprex Announces Positive Preclinical Results for GPX-002 - TipRanks
Genprex (GNPX) Unveils Promising Data for Diabetes Gene Therapy | GNPX Stock News - GuruFocus
Genprex Announces Positive Data for Diabetes Therapy - TipRanks
Genprex's Strategic Share Sale: Balancing Dilution Risks with Clinical Milestones - AInvest
Genprex Enters $12.5M Stock Purchase Agreement - TipRanks
Genprex (GNPX) Announces Plan to Sell 15 Million Shares | GNPX Stock News - GuruFocus
Genprex Files for Resale of 15 Million Shares - MarketScreener
Genprex Files to Sell 15 Million Shares, Boosting Financial Strategy - AInvest
genprex regains nasdaq compliance but faces bid price challenge By Investing.com - Investing.com Nigeria
genprex regains nasdaq compliance but faces bid price challenge - Investing.com
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - mx.advfn.com
Genprex (NASDAQ:GNPX) Shares Down 2.8% – Should You Sell? - Defense World
Genprex to Participate at BIO 2025 International Convention - BioSpace
Genprex to Participate at BIO 2025 International Convention | GN - GuruFocus
Genprex to Participate at BIO 2025 International Convention | GNPX Stock News - GuruFocus
Genprex Opens Partnership Discussions for Cancer and Diabetes Gene Therapies at BIO 2025 - Stock Titan
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting | GNPX Stock News - GuruFocus
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Nasdaq
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting | GNPX Stock News - GuruFocus
Genprex (GNPX) Reports Promising Preclinical Data for Diabetes Gene Therapy | GNPX Stock News - GuruFocus
Breakthrough Gene Therapy Could Transform Diabetes Treatment: New Preclinical Data Reveals Promising Results - Stock Titan
Finanzdaten der Genprex Inc-Aktie (GNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):